Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer - Takeaways - MDSpire

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer

  • By

  • Alberto Farolfi

  • Chiara Casadei

  • Emanuela Scarpi

  • Eleonora Paoletti

  • Caterina Gianni

  • Michela Palleschi

  • Nicola Gentili

  • Marita Mariotti

  • Sara Testoni

  • Giandomenico Di Menna

  • Francesca Rusconi

  • Alice Andalò

  • Olga Serra

  • Filippo Merloni

  • Marianna Sirico

  • Roberta Maltoni

  • Lorenzo Cecconetto

  • Samanta Sarti

  • Antonino Musolino

  • July 14, 2026

Share

  • 1

    Cervical cancer is a major cause of cancer-related mortality, particularly in advanced stages that are challenging to treat.

  • 2

    The INTERLACE and KEYNOTE-A18 trials showed improved progression-free survival and overall survival with induction chemotherapy and pembrolizumab.

  • 3

    Bevacizumab has been established as standard care for advanced cervical cancer, improving overall survival despite increased adverse events.

  • 4

    The KEYNOTE-826 trial demonstrated that pembrolizumab combined with platinum-based chemotherapy significantly prolonged survival.

  • 5

    A comparative effectiveness analysis using TriNetX data aims to assess the impact of platinum choice and bevacizumab on outcomes in advanced cervical cancer.

Original Source(s)

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer

  • by Alberto Farolfi, Chiara Casadei, Emanuela Scarpi, Eleonora Paoletti, Caterina Gianni, Michela Palleschi, Nicola Gentili, Marita Mariotti, Sara Testoni, Giandomenico Di Menna, Francesca Rusconi, Alice Andalò, Olga Serra, Filippo Merloni, Marianna Sirico, Roberta Maltoni, Lorenzo Cecconetto, Samanta Sarti, Antonino Musolino

  • July 14, 2026

Related Content

The regulatory role of IL-37 and IL-38 in CAR-T associated cytokine release syndrome in multiple myeloma

Robotic versus open pancreaticoduodenectomy in elderly patients: a meta-analysis

Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer